BMI1 and prostate carcinoma: More importantly, using two CRPC patient-derived xenograft (PDX) models11—LuCaP 35CR and 86.2CR—we further confirmed the interactions between AR and BMI1 in prostate cancer patient tissues (Fig. 1g).